FDA’s Woodcock Cautions Efforts To 'Legislate A New Generation Of Biomarkers'

This article was originally published in The Pink Sheet Daily

21 Oct 2015
News

Laura Helbling @Laura_H laura.helbling@previsionpolicy.com

Executive Summary

New approaches to biomarker qualification is big part of industry’s agenda for '21st Century Cures,' but CDER Director Janet Woodcock remains concerned about efforts to legislate ahead of the science.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

United States

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical United States Regulation

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS077903

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS077903

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

FDA’s Woodcock Cautions Efforts To 'Legislate A New Generation Of Biomarkers'

News

Executive Summary

Related Content

PDUFA VII Already: Could Breakthrough Ideas Apply Outside Program?

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert